<DOC>
	<DOC>NCT02299089</DOC>
	<brief_summary>This is a Phase II, open-label multicentre, randomised study to assess the PK, PD, efficacy, and safety of two dosing regimens of CAM2029 in adult patients with acromegaly or a functional, well-differentiated NET, with carcinoid symptoms.</brief_summary>
	<brief_title>Phase II Study of Subcutaneous Injection Depot of Octreotide in Patients With Acromegaly and Neuroendocrine Tumours (NETs)</brief_title>
	<detailed_description>This is a Phase II, open-label multicentre, randomised study to assess the PK, PD, efficacy, and safety of two dosing regimens of CAM2029 in adult patients with acromegaly or a functional, well-differentiated NET, with carcinoid symptoms, treated for at least 2 months with Sandostatin LAR at doses of 10 mg, 20 mg, or 30 mg before the start of the Sandostatin LAR Last Dose Assessment Phase (Day -28).</detailed_description>
	<mesh_term>Neuroendocrine Tumors</mesh_term>
	<mesh_term>Carcinoid Tumor</mesh_term>
	<mesh_term>Acromegaly</mesh_term>
	<mesh_term>Octreotide</mesh_term>
	<criteria>Acromegaly: Male or female patients ≥18 years of age Acromegaly currently treated with Sandostatin LAR NET: Male or female patients ≥18 years of age Functional, welldifferentiated (Grade 1 or Grade 2) NET with symptoms of carcinoid syndrome (number of bowel movements and/or flushing) Currently treated with Sandostatin LAR for symptom control Acromegaly: Inadequate bone marrow function Abnormal coagulation or chronic treatment with warfarin or coumarin derivates Impaired liver, cardiac and/or renal function Known gallbladder, bile duct disease or pancreatitis Diabetes with poorly controlled blood glucose levels despite adequate therapy Hypothyroidisms not adequately treated NET: Poorly differentiated neuroendocrine carcinoma, highgrade neuroendocrine carcinoma, adenocarcinoid, pancreatic islet cell carcinoma, insulinoma, glucagonoma, gastrinoma, goblet cell carcinoid, typical and atypical lung carcinoids, large cell neuroendocrine carcinoma and small cell carcinoma Carcinoid syndrome refractory to treatment with conventional doses of somatostatin analogues (SSAs) Inadequate bone marrow function Abnormal coagulation or chronic treatment with warfarin or coumarin derivates Impaired liver, cardiac and/or renal function Known gallbladder, bile duct disease or pancreatitis Shortbowel syndrome Diabetics with poorly controlled blood glucose levels despite adequate therapy Hypothyroidism, not adequately treated</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>acromegaly</keyword>
	<keyword>neuroendocrine tumour (NET)</keyword>
	<keyword>carcinoid syndrome</keyword>
	<keyword>octreotide</keyword>
	<keyword>Sandostatin LAR</keyword>
</DOC>